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Purpose. The aims of the study are to develop and evaluate an in vitro rat intestine segmental perfusion
model for the prediction of the oral fraction absorbed of compounds and to assess the ability of the
model to study intestinal metabolism.
Methods. The system consisted of a perfusion cell with a rat intestinal segment and three perfusion
circulations (donor, receiver, and rinsing circulation). Lucifer yellow (LY) was applied as internal
standard together with test compounds in the donor circulation. To validate the model, the permeability
of eight noncongeneric passively absorbed drugs was determined. Intestinal N-demethylation of
verapamil into norverapamil was followed in the donor and receiver circulations by high-performance
liquid chromatography analysis.
Results. The in vitro model allowed ranking of the tested compounds according to their in vivo
absorption potential. The Spearman’s correlation coefficient between the oral fraction absorbed in
humans and the ratio of permeation coefficient of test compound to the permeation coefficient of LY
within the same experiment was 0.98 (P < 0.01). Moreover, intestinal N-demethylation of verapamil, its
permeation, and the permeation of its metabolite norverapamil could be assessed in parallel.
Conclusions. Up to six permeation kinetics can be obtained per rat, and the method has shown to be a
valuable tool to estimate human oral absorption.
KEY WORDS: absorption model; in vitro intestinal metabolism; in vitro intestinal permeability; in
vitroYin vivo correlation; rat jejunal perfusion.
INTRODUCTION
Developing new chemical entities administered orally
and improving their bioavailability are key objectives in drug
research. Approaches allowing to evaluate extent, character-
istics, and mechanisms of absorption without having to study
bioavailability in vivo in whole animals are essential to
rationally select new viable chemical entities and optimize
lead candidates. Various biological models for permeability
investigations have been established at different levels of
complexity ranging from intestinal membranes to tissue-
based systems and in situ intestinal perfusion techniques.
Subcellular fractions and freshly isolated enterocytes are
limited to uptake studies rather than to transport studies, and
extrapolation to rate and extent of absorption in vivo is
difficult (1,2). Cell-based assays using human colon adeno-
carcinoma (Caco-2) or dog kidney (Madin-Darby canine
kidney) cell lines are frequently used to estimate drug
permeability. In comparison to animal studies, cell-based
assays are less expensive, well suited for high-throughput
screening, and allow to obtain reproducible permeability
values that correlate with intestinal absorption in humans
(3Y5). On the other hand, cell lines are generally composed
solely of absorptive cells and lack mucus, whereas the
intestinal epithelium consists of a monolayer of heteroge-
neous cells including enterocytes, goblet cells secreting
mucin, endocrine cells, and M cells. In addition, as the
transepithelial electrical resistance is far higher in cell
systems than in typical small intestinal tissue, the paracellular
permeability is often underestimated. Moreover, the expres-
sion of carriers and efflux systems is clearly different in
intestinal cell cultures compared to the in vivo situation (1,6).
In comparison to simpler models, the presence of apical
mucus layer in the tissue-based approaches is an improve-
ment, as it may possibly influence the absorption of
compounds. Two different in vitro methods relying on
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isolated tissues have been recurrently used to evaluate drug
permeability, measure paracellular transport, and determine
regional variability, namely, the everted gut sac technique
and the side-by-side Ussing chambers (7Y9). In the former
method, segments of intestine are turned inside out over a
glass rod, tied off at one end, filled with oxygenated buffer,
and ligatured at the other end. The resulting sacs are
incubated in the presence of test compound for different
time periods, and accumulation in the inner compartment is
measured. A high tissue viability and integrity was confirmed
for up to 120 min when using oxygenated tissue culture
medium 199 (7). However, the fluid inside the sac is stagnant,
which does not correspond to physiological conditions. In
Ussing chambers, the intestine is cut into strips, which are
clamped between two glass chambers filled with buffer and
nutrients such as glucose. In this setup, the permeation
studies can be conducted on intestinal tissue either with or
without the underlying muscle layers (10). Because drug
absorption into the intestinal vasculature in vivo does not
involve permeation through the intestinal smooth muscle, the
removal of this nonphysiological diffusion barrierVa practice
known as strippingVis claimed to be preferable because this
resembles more closely the in vivo situation (1). A high
correlation was reported between the effective permeability
coefficients determined in human jejunum in vivo and in
stripped excised jejunal rat segment in Ussing chambers for a
discrete small series of 12 compounds (11). However, the
procedure to remove the outer muscle layers from intestinal
segments requires extensive expertise in microsurgery and
may present a technical barrier to the novice scientist.
Compared to the in vitro models described above, in situ
approaches provide experimental conditions closer to what is
encountered following oral administration. In situ intestinal
perfusion experiments provide an intact blood supply and a
functional intestinal barrier. However, these techniques are
time and animal consuming and not adapted for high-
throughput screening (12).
In summary, as absorption models increase in complex-
ity, an increasing number of factors influencing drug absorp-
tion come into play. Unfortunately, the more closely the
model approaches the in vivo situation, the more it is labor
intensive and material and animal consuming (13).
The newly developed in vitro rat intestine segmental
perfusion model described here is a tissue-based system with
perfusion circulations, avoiding stagnant fluid inside the
intestinal segment. Up to six experiments per rat can be
performed, and less tissue manipulation is required than with
Ussing chambers. Because the oral fraction absorbed in vivo
in rats has been shown to correlate well with that in humans,
this rodent was selected as animal model (14,15). Character-
ization and evaluation of the segmental perfusion model was
performed by determining the permeation of eight passively
absorbed drugs with a broad range of physicochemical
properties and oral fractions absorbed in vivo. A good in
vitroYin vivo correlation was obtained, the Spearman’s
correlation coefficient between the oral fraction absorbed in
humans and the ratio of permeation coefficient of test
compound to the permeation coefficient of Lucifer yellow
(LY ) within the same experiment being 0.98 (P < 0.01).
Finally, preliminary experiments showed the possibility to
study metabolism and permeation of drugs and their
metabolites in parallel with the proposed in vitro perfusion
model. Verapamil and its N-demethylated metabolite nor-
verapamil were selected as model compounds, as studies of
their absorption and metabolism in rat assessed in Ussing
chambers (16Y18) and in two in situ models (19) are available
for comparison (20).
MATERIALS AND METHODS
Chemicals
Antipyrine, racemic atenolol, LY CH, mannitol, [2-(R),
3-(S)]-nadolol, (S)-(+)-naproxen, racemic norverapamil, ra-
cemic propranolol, sulpiride, testosterone, and racemic
verapamil were purchased from Sigma (St. Louis, MO,
USA). Polyethylene glycol 4000 (PEG 4000) was obtained
from Fluka Biochemica Ultra (Buchs, Switzerland). D-
[1-14C]Mannitol, [14C]PEG 4000, and [4-14C]testosterone
were acquired from Amersham Pharmacia Biotech (Bucking-
hamshire, UK). (D,L)-[Ring-3H(N)]Atenolol and L-[4-
3H]propranolol were purchased from NEN Life Science
Products (Boston, MA, USA). [3-14C]Antipyrine and
medium 199 with Earle’s salts, L-glutamine, and bicarbonate
were obtained from Sigma.
All other chemicals were of analytical grade, and
analytical solvents were of high-performance liquid chroma-
tography (HPLC) grade and purity. The Oasis HLB extrac-
tion cartridges (10 mg) were supplied by Waters Corporation
(Milford, MA, USA).
Animals and Surgery
Male albino Sprague-Dawley rats (250Y400 g) obtained
from Charles River Lab (Iffa Credo, L’Arbresle, France)
were allowed to acclimatize in our facilities for at least 4 days
before sacrifice. They were maintained in cages in an air-
conditioned room (21Y25-C, 50% humidity) with circadian
day/night rhythm of 12 h. Standard rodent chow (No. 950.9,
Protector S.A., Lucens, Switzerland) and water were given ad
libitum. Before the experiment, rats were fasted overnight.
The protocol of these studies was approved by the Cantonal
Veterinary Service (VD, Switzerland) and was in compliance
with the BPrinciples of Laboratory Animal Care^ (NIH
publication #85-23, revised 1985). Once euthanized by anoxia
with carbonic gas, upon verification of the loss of pain reflex,
rats were placed on their back, restrained to the operating
platform with adhesive band, and a ventricular longitudinal
incision was made from the pubis to just below the
diaphragm. Perpendicular incisions at the ends of the
longitudinal incision allowed the exposition of the peritoneal
cavity. The small intestine was quickly removed, placed in an
oxygenated physiological NaCl solution at 37-C, and rinsed
with approximately 50 mL oxygenated physiological NaCl
solution to remove food particles. The jejunum (segment of
20 cm beginning 30 cm distal to the pylorus) was used for
perfusion experiments (10).
Description of the in Vitro Segmental Perfusion System
The in vitro segmental perfusion system consisted of the
perfusion cell, three perfusion circulations (donor, receiver,
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and rinsing circulation including peristaltic pumps and
thermostated reservoirs with oxygenation), two bubble traps,
an oven, and four three-way stopcocks (see Fig. 1A). The
donor medium circulated through the inside of the intestinal
segment, while the receiver circulation was flowing outside
the intestinal segment, in the opposite direction. The rinsing
circulation was needed to facilitate air-bubbles extraction in
the segment and to provide a good tissue oxygenation
before initiating the experiments. All circulations were
thermostated at 37-C, and their oxygenation was assured
by bubbling their reservoirs with Carbogen (95% O2, 5%
CO2) under magnetic stirring. The flow rates were estab-
lished by means of an Ismatec VC-MS/CA peristaltic pump
(Ismatec, Zurich, Switzerland) for the rinsing circulation
(pump 1), a Masterflex\ PTFE-tubing pump (Cole-Parmer
Instrument Company, Vernon Hills, IL, USA) for the donor
circulation (pump 2), and an LC T-414 pump (Kontron
Instruments, Zurich-Mu¨llingen, Switzerland) for the receiver
circulation (pump 3).
The present studies were performed on two identical
systems, allowing two kinetics to be carried out in parallel.
Preparation of Segments
The central element of the segmental perfusion system
consisted of two hollow cylindrical ends connected with
concave junctions and allowing the head of one central
element to fit into the back of another (Fig. 2). Both hollow
cylindrical ends (diameter 0.4 cm) presented a groove. A cap
was placed on the head to facilitate introduction in the
jejunum.
Avoiding areas containing Peyers patches, both ends of
the segments were ligated on the grooves using silk suture.
The so-obtained intestinal segments were kept in oxygenated
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Fig. 1. Schematic of the in vitro rat intestine segmental perfusion system with its permeation cell, shunt,
bubble traps, oven, and three perfusion circulations (A). Before the installation of the permeation cell,
the four three-way stopcocks are oriented to block issues A, E, G, and L, while only rinsing
circulation’s pump 1 is working (B). After the installation of the permeation cell, issues C, D, I, and J
are blocked, while the three pumps are switched on (C). Finally, during the permeation kinetic, issues
B, F, J, and K are blocked and pump 1 is stopped, so that the oxygenated donor circulation flows
without air bubbles inside the segment, whereas the receiver circulation flows outside the segment in
the opposite direction (D).
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physiological solution, installed on the bottom part of the
perfusion cell, and cap-removed (Fig. 2). Then, the perfusion
cells were assembled, and the segments were rinsed with 3
mL of oxygenated medium before being inserted in the
perfusion systems.
In Vitro Permeation Experiments
with the Perfused Segment
The reservoirs of the receiver and rinsing circulations
were filled with 15.0 mL of medium 199. In the donor
reservoir, 15.0 mL of medium 199 containing the test
compound and LY as internal standard, each at a concentra-
tion of 100 mM, was inserted (Fig. 1A). The proportion of
radiolabeled test compound was calculated to reach 200,000
dpm/mL in the donor solution.
Three different flow rates (0.2, 0.4, and 0.6 mL/min) were
tested for both the rinsing and donor circulations to study the
influence of this parameter on the permeation kinetics. During
the installation of the perfusion cell into the perfusion system,
the three-way stopcocks were oriented to block issues A, E, G,
and L (Fig. 1B), permitting circulation of oxygenated medium
199 from the rinsing reservoir to waste via a shunt. Peristaltic
pump 1 was set to the selected flow rate.
After installation of the perfusion cell, the orientation of
the three-way stopcocks was modified to block issues C, D, I,
and J. Consequently, the oxygenated rinsing solution circu-
lated in the segment at the selected flow rate (Fig. 1C).
During that time, pump 3 was switched on to allow the
receiver circulation to pass outside the segment at 3.0 mL/
min. In addition, the donor circulation was homogenized with
the medium remaining from the shunt at a high flow rate
(5 mL/min) by switching on pump 2.
After extraction of potential air bubbles in the segment
using a syringe on the upper bubble trap, the tissue was
allowed to equilibrate for 10 min to facilitate reestablishment
of ion transport and ensure a good homogenization in the
donor circulation.
After this equilibration time, about 45 min after
euthanasia of the animal, 150 mL of sample was withdrawn
from the donor reservoir to measure initial LY and test
compound concentrations. Pump 1 was switched off, and the
flow rate of pump 2 was set to the experimental condition
(0.2, 0.4, or 0.6 mL/min). The three-way stopcocks were
oriented to close the issues B, F, H, and K, allowing the
donor fluid to go through the intestinal segment (time t0, see
Fig. 1D). The pH values of the donor and receiver solutions
were measured before and after the experiments. During
approximately 2 h of permeation study, samples (150 mL for
compound and LY analysis) were removed every 10Y15 min
from the receiver circulation and replaced with the same
volume of medium.
Evaluation of in Vitro Metabolism and Permeation
of Verapamil
To evaluate the chemical stability of verapamil and
norverapamil and their possible adsorption onto the perfu-
sion system, 1 mM solutions of these compounds were
prepared in medium 199 and circulated in the receiver
circulation at 37-C for 3 h with a piece of stainless steel in
place of the intestinal segment.
Animal surgery and preparation of the segments were
performed as described above. The flow rate was set at 3 mL/
min in the receiver circulation and at 0.4 mL/min in the other
circulations. The permeation kinetics of parent verapamil
and LYVboth at an initial donor concentration of 100
mMVwere monitored in the donor and receiver circulations
for verapamil and in the receiver circulation for LY. The
appearance of the metabolite norverapamil as a function of
time was investigated in both circulations. Because the flow
rate in the donor circulation was low, resulting in poor
homogenization, samples from this circulation were taken
after the perfusion cell, just before the return into the donor
reservoir (see Fig. 1A). The time course of the metabolism
experiments was extended to 150 min, and samples were
removed every 10 min, alternatively from the donor and
receiver circulations. The volume removed (200 mL) was
replaced with an identical volume of medium 199 only in the
receiver circulation.
Analytical Methods
Lucifer yellow and naproxen were assayed alone or
together by HPLC on a liquid chromatograph Waters 2690
Separation module (Waters, Millipore) equipped with a
Perkin-Elmer LC240 fluorescence detector (Perkin-Elmer,
Beaconsfield, UK). The excitation and emission wavelengths
were respectively set to 420 and 520 nm for LY and to 270
and 360 nm for naproxen. The HPLC column was a
LiChrospher 100 RP-18e (125  4 mm i.d., 5 mm). The
isocratic mobile phase consisted of 85% v/v phosphate buffer
pH 7.0 and 15% v/v acetonitrile. Calibration curves were
calculated to determine concentrations. There was no inter-
ference from the medium, tissue-related substances, or tested
compounds.
Norverapamil and verapamil were assayed on the HPLC
system described above, according to a published method
(16). The samples were injected onto an Xterra MS C18
column (150  3.9 mm i.d., 5 mm) and detected by
fluorescence with excitation and emission wavelengths set
to 280 and 310 nm, respectively. Baseline separation of
Fig. 2. Preparation of tissue segments.
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norverapamil from verapamil was complete in the calibration
range from 0.02 to 1 mM of norverapamil, independently of
the verapamil concentration (0.02Y150 mM). Standard curves
for verapamil were established from 0.02 to 150 mM.
The amount of radioactive test compounds in the
receiver or donor solutions was monitored using Ultima
Goldi scintillation cocktail from Packard (Pangbourne,
UK) and a Packard liquid scintillation counter.
Nadolol was isolated from samples by solid-phase
extraction and assayed by liquid chromatography coupled to
mass spectrometry using electrospray ionization (LC-MS/
MS). Specifically, 200-mL samples diluted ten times and 20.0
mL of sulpiride used as internal standard (stock solution, 200
nM) were extracted from an automated solid-phase extrac-
tion system using Oasis cartridges previously solvated with
methanol (350 mL) and purified water (350 mL). After
washing with 500 mL purified water, nadolol and sulpiride
were eluted with 150 mL methanol twice and evaporated to
dryness under nitrogen at 37-C. The dry extracts were
reconstituted with 200 mL of the isocratic mobile phase
(50% v/v ammonium formate 20 mM and 50% v/v 0.05%
formic acid/acetonitrile). A Quattro LC mass spectrometer
(Micromass, Manchester, UK) equipped with an electrospray
ionization interface in positive mode with multiple reaction
monitoring and Masslynx V 3.4 system software was used for
detection. The HPLC system consisted of an Alpha MOS
CTC injector maintained at 10-C (Alpha MOS, Toulouse,
France) interfaced to a separation module Agilent 1100
series (Agilent Technologies, Palo Alto, CA, USA). A Hy
Purity C18 (10  2.1 mm i.d., 5 mm) guard column and a Hy
Purity C18 (150  3.0 mm i.d., 5 mm) column were used for
the chromatographic separations. The isocratic mobile phase
was set at a flow rate of 0.2 mL/min, and the tuning
parameters were optimized to yield best sensitivity. The
calibration range was from 2.5 nM to 2 mM.
Calculations
The apparent permeability coefficient (Papp) of each
drug was calculated according to Eq. (1), where dQ/dt is the
steady-state appearance rate in the receiver circulation, r is
the radius of the intestinal tract (0.2 cm), L is the exposed
length of tissue (3 cm), and C0 is the initial concentration of
drug in the donor circulation.
Papp ¼ dQ
dt
1
2rLC0
cm=sð Þ ð1Þ
LY was used as internal standard in all experiments, and
the results were expressed as the ratio of the Papp of test
compound to the Papp of LY determined in the same
experiment (Papp/Papp LY).
Spearman’s rank correlation coefficient (rs), used as a
measure of linear relationship between two sets of ranked
data, was calculated with Prism 4.0 software (Graphpad, San
Diego, CA, USA) according to Eq. (2), where d is the
difference of the two ranks associated with each compound
and n is the number of compounds.
rs ¼ 1 6
P
d2
n3  nð Þ ð2Þ
RESULTS
Development of the in Vitro Rat Intestine Segmental
Perfusion Model
The development of the in vitro rat intestine segmental
perfusion model involved the consideration and optimization
of various factors, among others adsorption phenomena onto
the materials used, tissue viability, flow rates of the perfusion
circulations, choice of an internal standard, and reproducibil-
ity of the results.
Preliminary experiments showed that testosterone was
highly adsorbed onto tubing of Silicone > Tygon\ >>
Norprene\ >> Viton\. In contrast, no binding was observed
(after 2 days at room temperature) onto Teflon\ or
Plexiglas\. Therefore, Teflon\ tubing was chosen for the
whole system including the peristaltic pumps. The central
element was built of stainless steel, and the perfusion cells
were made of Plexiglas\. No adsorption of any of the
investigated compounds onto these materials was observed.
The flow rate of the receiver circulation was set to 3
mL/min, which was the lowest rate resulting in sufficient
homogenization of the receiver circulation and allowing
representative samples to be taken every 10Y15 min (data
not shown). The flow rate of the donor circulation was
varied between 0.2 and 0.6 mL/min. For flow rates of 0.2
and 0.4 mL/min, reliable and reproducible results were
obtained (Table I). When increasing the gastrointestinal
donor flux to 0.6 mL/min, altered nonlinear permeability of
the internal standard LY and the tested compound occurred
frequently (data not shown). A donor circulation flow rate
between 0.2 and 0.4 mL/min was therefore chosen in all
further experiments.
As illustrated in Fig. 3 with two representative perme-
ation studies, the kinetics of permeation and the Papp of the
tested compounds varied considerably between experiments.
However, the ratio of the Papp of test compound to the Papp
of the internal standard LY in the same experiment was
highly reproducible (Table I). Indeed, the example of
mannitol (Fig. 3) shows that at a donor circulation flow rate
of 0.4 mL/min, the Papp of mannitol and LY were 29 and 15
(10j6 cm/s) for rat A and 17 and 9 (10j6 cm/s) for rat B,
respectively, whereas the ratios between the Papp of mannitol
and LY were 1.9 in both experiments. These results clearly
show that an internal standard is essential to obtain
reproducible results.
Table I. Influence of the Flow Rate in the Donor Circulation on the
Ratios of the Papp of Test Compounds to the Papp of LY in the Same
Experiment
Compound
Donor circulation flow rate
0.2 mL/min 0.4 mL/min
Ratioa n Ratioa n
Antipyrine 3.6 T 0.1 3 3.7 T 0.1 3
Naproxen 2.6 T 0.2 3 2.6 T 0.3 10
Mannitol 2.2 1 1.9 T 0.2 3
Atenolol 1.2 1 1.1 T 0.1 4
aMean T standard deviation.
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LY is an internal standard with intermediate intestinal
permeability (Table II). To evaluate the benefit of a second
reference compound with high intestinal permeability, nap-
roxen was inserted in the donor circulation together with LY
and test compound (each at 100 mM). The permeability of all
compounds at a donor circulation flow rate of 0.4 mL/min
was determined at least once with both LY and naproxen as
internal standards. The presence of naproxen had no
influence on the ratios between the Papp of the tested
compounds and the Papp of LY. Because the ratio of the
Papp of the two internal standards tested, i.e., naproxen to
LY, was the same within experimental errors (Table I), the
use of a second internal standard was not considered
necessary. LY was chosen as reference compound in all
further experiments.
The pH measured in the oxygenated reservoirs at 37-C
was always between 7.2 and 7.4 during the whole experimen-
tal procedure. The highest concentration in the receiver
circulation at the end of the 2-h perfusion was at most 10% of
the initial concentration in the donor circulation.
Permeation Studies
The in vitro rat intestine segmental perfusion model was
validated by comparing apparent permeability ratios (Papp/
Papp LY) of eight compounds with the fraction of dose
absorbed in man (Fa). The ratios of the Papp of test
compound to the Papp of LY in the same experiment (donor
flow rates of 0.2 or 0.4 mL/min inside the segment) are
presented in Table II together with literature Fa values and
some physicochemical properties important for permeability
Fig. 3. Representative permeation kinetics of mannitol (0, rat A; Í,
rat B) using Lucifer yellow (LY ) as internal standard (>, rat A; Ì, rat
B) with a flow rate of 0.4 mL/min in the donor circulation. The Papp
of mannitol was different between the experiments, but the ratio to
the internal standard was the same.
Table II. Physicochemical Properties, Oral Fraction Absorbed (Fa), and Apparent Permeability Ratios Determined with the in Vitro Rat
Intestine Segmental Perfusion Model (Papp/Papp LY), Together with Literature Permeability Values in Ussing Chambers (Papp) and in Situ
Perfusion (Peff)
Compound MW pKa
a log PNa log D7:4oct
b
Fa in vivo in
humans (%)
Ratio Papp /
Papp LY T SD
(nb jejunal
segments)
Ussing chambers
(jejunum), Papp T SD
(10j6 cm/s) c
Single-pass
intestinal perfusion
(ileum), Peff T SD
(10j6 cm/s)d
Testosterone 288 Y 3.32 3.32 100 e 5.9 T 0.2 (3) n.i. 50 T 15 f
Antipyrine 188 1.44 0.56 0.34 97T5 g 3.7 T 0.1 (6) 40 T 7 73 T 2
Naproxen 230 4.18h 3.06h 0.23 99 i 2.6 T 0.3 (13) 39Y51 167 T 82
Propranolol 259 9.53 j 3.48 j 1.26 90kY100 l 2.5 T 0.1 (3) 29 T 2 66 T 29
Mannitol 182 Y j3.10 j3.10 65m 1.9 T 0.2 (4) 5.9 T 2.3 7 T 5 g
Atenolol 266 9.54 j 0.22 j j1.29 37Y71n 1.1 T 0.1 (6) 6.0 T 0.3 18 T 9
Lucifer yellow 457 n.i. Y Y n.i. 1 n.i. n.i.
Nadolol 309 9.67 0.71 0.68 20 T 2o 0.7 T 0.2 (3) n.i. 4.3 T 0.7
PEG 4000 4000 Y Y Y 0m 0 (2) 0p 0 p
The Peff in single-pass perfusion were all taken from references using segments of ileum, luminal pH 7.4 solutions, and 0.2-mL/min flow rate.
n.i. : no information available.
a log P and pKa from the MedChem 95 database.
bData from (39) except for testosterone and mannitol, where log D = log P.
cData obtained from (9,11), the pH of the donor and receiver solutions being 7.4.
dData from (12).
eData from (40).
fData from (41).
gData from (42).
hData from (43).
iData from (14).
jData from (44).
kData from (5).
lData from (45).
mData from (22). Note that the value reported for mannitol absorption is higher than other values reported in the literature. Some of this
discrepancy may be caused by the apparent hepatic metabolism of mannitol to CO2, which is not accounted for in some studies (46). The
higher value is consistent with the current data and also with previous published results (22).
nData from (47).
oData from (48).
pData from (21).
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prediction. The permeability coefficients obtained for the
same compounds in Ussing chambers and in single-pass
intestinal perfusion are also reported in Table II to compare
the predictive value for intestinal absorption of the devel-
oped method with the one of these techniques. In Ussing
chambers, the coefficients of permeation are based on the
appearance of the compound in the receiver compartment
(Papp), whereas in the single-pass intestinal perfusion tech-
nique, the effective permeability coefficients (Peff) refer to
the disappearance of the compound in the lumen.
A plot of the apparent permeability ratios against the
oral fraction absorbed in humans is presented in Fig. 4 and
shows a good in vitroYin vivo correlation. Indeed, the in vitro
rat intestine segmental perfusion model allowed ranking of
the tested compounds according to their oral absorption
potential in humans with a Spearman’s rank correlation
coefficient calculated for apparent permeability ratios and
oral fractions absorbed in humans of 0.98 (P < 0.01).
Interestingly, the appearance rate of propranolol in the
receiver circulation was nonlinear at the beginning of the
experiments, reached steady state around 60 min, and showed
a linear time course for the next 60 min. The permeation
kinetics of LY in the same experiments were linear from the
beginning of the experiment and in a normal range, which
confirmed integrity of the tissue. The Papp of propranolol was
calculated at steady state, and the ratio between the Papp of
propranolol and the one of LY within the same experiment
was highly reproducible (2.5 T 0.1) and consistent with the
high oral fraction absorbed in vivo (Table II).
Preliminary Metabolism Studies
The chemical stability of verapamil and norverapamil
and their possible adsorption onto the perfusion system was
evaluated by circulating 1-mM solutions of these compounds
in medium 199 in the receiver circulation at 37-C for 3 h with
a piece of stainless steel in place of the intestinal segment.
The concentration of both solutions remained constant, and
neither degradation nor adsorption was observed.
Preliminary metabolism and permeation experiments of
verapamil with the in vitro perfusion model showed that
verapamil was N-demethylated to norverapamil in the jejunal
segment. The metabolism as well as the permeation of the
parent compound and the metabolite could be followed in
parallel, as shown in Fig. 5. Because the permeation of LY
was linear and in the same range within the four in vitro
metabolism/permeation experiments performed, the concen-
tration time profiles of verapamil and its metabolite in the
donor circulation at the exit of the perfusion cell (Fig. 5A)
and in the receiver circulation (Fig. 5B) were compiled. The
net apparent extraction of verapamil from the donor
circulation by the intestinal segment remained stable during
the time course of the experiment (Fig. 5A). Additionally, an
increasing amount of norverapamil was secreted back into
the luminal perfusate with respect to time. As was the case
with propranolol, a delay was observed before the passage of
verapamil into the receiver circulation reached steady state,
whereas the passage of LY was linear (Fig. 5B). The ratio of
the Papp of parent verapamil calculated at steady state to the
Papp of LY in the same experiment was 2.7 T 0.4 (n = 4).
Fig. 4. Plot of the ratio of the rat jejunal permeability coefficient of
compounds to the permeability coefficient of LY in the same tissue
against oral fraction absorbed in humans. Compounds: (1) testoster-
one, (2) antipyrine, (3) naproxen, (4) propranolol, (5) mannitol, (6)
atenolol, (7) nadolol, and (8) PEG 4000. aClassification according to
(25) and (26).
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Fig. 5. Concentration time profiles of verapamil (&) and formation
of norverapamil (Í) in presence of LY (r) at the donor exit of the
perfusion cell (A) and in the receiver circulation (B) (n = 4).
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DISCUSSION
Validated Experimental Setup for the in Vitro
Perfusion Model
A valuable in vitro intestinal absorption system should
respect the relevant characteristics of the functional intestinal
barrier in vivo as closely as possible, be reproducible, and be
easy to use. Low animal requirement, conservation of a good
tissue viability, and prospect for automation would be
advantageous. Considering these requirements, an in vitro
rat intestine segmental perfusion model was developed.
To improve tissue viability, intestinal segments were
kept in tissue culture medium 199 (7) and oxygenated with
carbogen (95% O2, 5% CO2).
Experiments performed to optimize the donor circula-
tion flow rate showed that the ratios of the Papp of test
compound to the Papp of LY in the same experiment were
highly reproducible when the donor circulation flux was set
to 0.2 or 0.4 mL/min. Furthermore, there was no significant
difference between the ratios at both fluxes (P < 0.05, Table
I). However, when this flux was risen to 0.6 mL/min, the
kinetics of permeation frequently showed an altered perme-
ability for both tested compound and internal standard,
resulting in poor reproducibility of the permeation data. This
might be caused by turbulences within the intestinal segment
at this higher flow rate, but degradation of the mucus layer or
increased physical stress on the cells might be other
explanations. A donor circulation flow rate of 0.6 mL/min
was therefore considered to be too high. As the cumulated
amount seemed slightly higher and the homogenization was
supposed to be improved with a flow rate of 0.4 mL/min in
comparison to 0.2 mL/min, the experiments were carried out
preferentially at this higher flow rate. In addition, no
significant regional difference in the Papp values nor in the
Papp ratio of test compound to internal standard was
observed between the upper and lower parts of the rat
jejunum section used in this study.
The use of an internal standard is known to improve the
prediction of the oral absorption of drugs (22). With
predilection for a nonradioactive internal standard, LY was
preferred to fluorescein because the latter was reported to
present a nonpolarized transport poorly affected by pH via
passive paracellular pathways in Caco-2 cells (23). The
variability between experiments in coefficients of permeation
obtained for the compounds tested was radically reduced
when rationalizing with the coefficient of permeation of LY
in the same experiment (see Fig. 3 and Table I). This
variability in the Papp observed between experiments might
be explained by small changes of the donor flux, by variations
in the tissue surface exposed, or by interanimal variability.
Normalizing with the Papp of LY obtained under identical
experimental conditions than the test compound allowed
correcting for these variations. Moreover, LY was indicative
of tissue integrity and allowed rejection of leaky tissues,
which led to nonlinear, increased, and irrelevant kinetics.
Indeed, for leaky tissues, the permeation of both LY and
tested compound were not linear for the duration of the
experiment, suggesting that the tissue did not remain intact.
In summary, the presence of an internal standard turned out
to be essential for the validation of tissue integrity and for a
better relevance of results to predict in vivo oral absorption.
The use of a second internal standard with a high intestinal
permeability, e.g., naproxen, might corroborate the results,
but was not considered to be essential because the ratio
between the Papp of the two internal standards was constant
(Table I).
In the current version of the in vitro perfusion model,
the volume used in the donor reservoir was rather high (15
mL), which might limit its use to relatively inexpensive
compounds that can be used in micromolar concentrations.
However, the present prototype might be miniaturized to
limit this drawback.
Permeation Studies
The compounds selected for the validation of the system
presented very diverse physicochemical properties and were
chosen to cover the whole range of oral fractions absorbed,
from 0 to 100%. No values of log P and pKa are indicated for
PEG 4000 in Table II, as they are not relevant for a polymer.
LY is expected to have five pKa values below 5 (three acidic
and two basic) and to be ionized at neutral pH. Indeed, at pH
7.4, the two weakly basic groups are unionized, whereas the
three acidic groups (two sulfates and one N-acidic group) are
negatively charged. The stability in phosphate-based buffered
solutions at 37-C for 150 min was reported for the majority of
compounds tested (16,21). A potential effect because of
metabolism on the permeation rates might have influenced
the calculation of the permeability coefficients for some of
these compounds; however, this was not evaluated further in
this study.
As can be seen in Fig. 4, the new in vitro perfusion
model correctly divided the compounds into low (Fa < 20%),
medium (Fa = 20 Y 80%), and high (Fa > 80%) absorption
drugs, according to an extended version of the biopharma-
ceutics classification system (24) used by several authors
(25,26). Actually, the apparent permeability ratios were
predictive for a compound not absorbed at all in humans
(PEG 4000), as well as for intermediately absorbed com-
pounds (nadolol, LY, atenolol, and mannitol) and highly
absorbed drugs (propranolol, naproxen, antipyrine, and
testosterone). Most notably, the range of ratios between
poorly and highly absorbed drugs (0 Y2.5) allowed discrimi-
nation of intermediately absorbed drugs. Moreover, the lack
of absorption of PEG 4000 and its full recovery in the donor
circulation at the end of the experiments also assessed the
integrity of the intestinal mucosa in the segments. Interest-
ingly, the developed model suggested mannitol to be
absorbed at a higher extent than atenolol. This was consistent
with the value of fraction absorbed in humans reported in
Table II and also with previously published results (22). On
the other hand, both in Ussing chambers and in single-pass
intestinal perfusion, the extent of permeation of mannitol
was similar to the one of atenolol, but with high standard
deviations (Table II).
Spearman’s rank correlation coefficient between the
apparent permeability ratios (Papp /Papp LY) in the in vitro
rat intestine segmental perfusion model and oral fraction
absorbed in humans was 0.98 (P < 0.01), indicating the good
predictive power of the model. Comparison with in situ
single-pass intestinal perfusion and Ussing chambers
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strengthens the high predictive quality of the developed
model. Indeed, the coefficient of Spearman between the ileal
effective permeability in situ and the oral fraction absorbed
for the same series of compounds was 0.83 (P < 0.05). Peff
values in the ileum were used for comparison, as they were
available for all tested compounds under identical perfusion
conditions (flow rate at 0.2 mL/min, donor solution of pH
7.4) and as no statistical difference was reported between the
Peff in the jejunum and the ileum for a discrete series of
compounds (22). In Ussing chambers, no information was
available on the rat jejunal Papp of testosterone, nadolol, and
LY. Therefore, estimation of Spearman’s rank correlation
coefficient between Papp in Ussing chambers and Fa was not
considered relevant for comparison. Nevertheless, ranking of
the compounds according to their permeability was similar
between rat jejunal segments in Ussing chambers and in the
in vitro perfusion model (Table II), the pH of donor and
receiver medium being 7.4 in both setups.
In the Caco-2 model, the permeation kinetics of
propranolol presented a uniform linear passage across the
cells without delay and with similar Papp values, whether
calculated with or without metabolites (27). Hence, the delay
of 60 min observed to reach an apparent steady-state
permeation in the receiver circulation of the in vitro
segmental perfusion model was unlikely to be explained by
the formation of metabolites with different apparition
kinetics nor by a potential efflux mechanism or by physio-
logically relevant binding to components of the enterocytes.
In the literature, high accumulation of propranolol within
tissue of rat jejunum associated with poor permeability in
Ussing chambers during 1 h of experiment has already been
reported (28). Because propranolol was shown to present
high permeability in situ in agreement with the high oral
fraction absorbed for this compound, which is between 90
and 100% (Table II), the contradiction with the poor
absorption in the tissue-based in vitro model was suggested
to be the consequence of substantial differences in the
passage through the intestinal membrane between the in
vitro and the in situ situations (28). Indeed, in Ussing
chambers as well as in the in vitro rat intestine segmental
perfusion model, once the epithelium has been crossed, a
diffusion through the villiVand also eventually through the
remaining muscle layersVis necessary to reach the serosal
side. These phenomena do not occur in situ or in vivo where
the compound only has to diffuse to the vicinity of capillaries
adjacent to the basement membranes of absorptive cells in
the lamina propria of the villi (29). This nonphysiological
diffusion barrier present in in vitro tissue-based systems was
suggested to influence the permeation kinetics of cationic
lipophilic compounds binding to the villi and muscle layers.
Indeed, propranolol and sulfapyridine were shown to be
taken up by the jejunal tissue in the side-by-side diffusion
chambers model (28). It can thus be assumed that the initial
nonlinear time course of propranolol appearance in the
receiver solution detected was a result of tissue binding.
After 60 min, tissue binding reached saturation, and linear
permeation kinetics were observed. This is in agreement with
a permeation study during 180 min in Ussing chambers where
jejunal segments showed a lower Papp for propranolol after
60 min than after 120 min (30). Because the calculation of the
coefficient of permeation is based on the steady-state passage
of a compound, the appearance rate of test compounds in the
receiver circulation was estimated on the linear part of their
permeation kinetics, at steady state. Hence, the nonphysio-
logical diffusion barrier present in the in vitro rat intestine
segmental perfusion model is thought to influence the
permeation kinetics of cationic lipophilic compounds but
not their permeation coefficients calculated at steady state.
Indeed, the ratio of the Papp of propranolol to the Papp of LY
obtained was reproducible (Table II) and correctly predicted
a high Fa for propranolol (Fig. 4).
Preliminary Metabolism Studies
Because the small intestine not only acts as an absorp-
tive organ, but also as the first metabolic barrier encountered
by orally administered drugs, the ability of the developed in
vitro rat intestine segmental perfusion model to study both
metabolism and permeation in parallel is an asset. Verapamil
was selected as model compound because many data were
available on its absorption and metabolism in rat jejunum
(16Y20). Generally, these studies were performed with
extracted blood samples or in simple balanced salt solutions,
so that other metabolites of verapamil than norverapamil
could be detected. In the present preliminary study, these
metabolites were not separated from background peaks of
components of medium 199, and hence, only metabolism to
norverapamil was considered. The enzymes involved in the
N-demethylation of verapamil are cytochromes P450 3A,
which are implicated in the metabolism of more than 50%
of the drugs on the market (16,31,32). Because both
verapamil and its metabolite norverapamil are known to be
actively secreted back in the luminal tract by efflux trans-
porters, the appearance of norverapamil was also investigat-
ed in the donor circulation of our setup. Given that the flow
rate in the donor circulation was low (0.4 mL/min), sampling
in the reservoir would not have been representative of the
mean concentration in this circulation. Therefore, the ap-
pearance of norverapamil in the donor circulation was
monitored after the perfusion cell, just before turning back
into the donor reservoir. To be exposed to the cytochromes
P450 3A, which are located intracellularly in the mature
villous enterocytes (33), verapamil had to enter the cytosol of
these cells either once or several times, this drug being
substrate of efflux transporters. The increasing amount of
norverapamil secreted back into the luminal perfusate with
respect to time clearly demonstrated the functionality of the
CYP 3A in our setup throughout the 150 min of the
experiments, confirming the functionality of the tissue during
the time course of the experiments.
In the receiver circulation, as was the case with
propranolol, a delay was observed before the passage of
verapamil reached steady state, whereas the passage of LY
was linear (Fig. 5B). Tissue uptake of verapamil and an
apparent increase in the permeation rate of verapamil at a
20-mM donor concentration after 60Y90 min was also
documented in Ussing chambers (16). These observations
corroborate the hypothesis that the nonlinear permeation
kinetics exhibiting a marked delay before reaching steady
state in the in vitro rat intestine segmental perfusion model
were related to tissue binding. Because the transformation of
verapamil into other metabolites than norverapamil was not
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taken into account in the apparent permeation kinetics of
verapamil and because other supplementary samples were
taken from the donor side, the results obtained with this
compound were not compiled with the ones presented above
for the validation of the method. Nevertheless, the ratio of
the Papp of parent verapamil at steady state with an initial
donor concentration of 100 mM to the Papp of LY in the same
experiments was 2.7 T 0.4 (n = 4), predicting a high
absorption of verapamil, which was in good agreement with
its oral fraction absorbed of 100% (14).
Interest of the in Vitro Rat Intestine Segmental
Perfusion Model
In comparison to in situ techniques, the model presented
here is less close to the in vivo situation. However, up to six
segments of jejunum can be taken, and hence, up to six
permeation kinetics can be obtained per rat, which contrib-
utes to reduce animal consumption. As in the other tissue-
based in vitro systems, the apical mucus layer is present,
which is an advantage, as it may possibly influence the
absorption of compounds. Compared to Ussing chambers
and everted sacs, less tissue manipulation is required during
the preparation of the segments. In contrast to the cell-based
systems, the in vitro rat intestine segmental perfusion model
is not planned for high-throughput screening, but rather as a
complementary, user-friendly absorption test for new chem-
ical entities to comfort results obtained with simpler in vitro
models. The method described here offers the possibility to
evaluate the intestinal metabolism of drugs in parallel with
permeation studies of parent compounds and metabolites. It
is intended to allow a high experimental control (e.g., of
compound concentrations, perfusion rates, pH, and coadmin-
istration of absorption promoters, efflux, or metabolism
inhibitors). With its flexibility, the impact of most experi-
mental factors susceptible to influence the absorption of a
compound might be assessed separately, which is likely to
contribute to a better understanding of the mechanisms
involved in the absorption of a compound and to evaluate
metabolism and absorption interactions.
Recently, several attempts to develop models predicting
the absorption rate of drugs that take into account solid drug
dissolution and pH changes in the gastrointestinal tract have
been published (34Y38). Using the flexibility of the in vitro
rat intestine segmental perfusion model, perspectives of this
work include the replacement of the donor reservoir by a
traditional paddle dissolution chamber or even the installa-
tion of a flow-through cell dissolution apparatus with
subsequent flow reducers before reaching the perfusion cell.
Thus, with few adaptations, the proposed model might
evaluate the influence of excipients and formulation on the
permeation of poorly water-soluble drugs. Finally, future
sample automation is possible.
CONCLUSION
The developed in vitro rat intestine segmental perfusion
model has shown to be a valuable tool to estimate oral
absorption of compounds in humans. It allowed ranking of
the tested compounds according to their oral absorption
potential. Additionally, it was demonstrated that the perme-
ation and metabolism of a drug, as well as permeability
characteristics of metabolites formed from the parent com-
pound, can be evaluated in parallel.
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